May 9, 2017 / 12:44 PM / 3 months ago

BRIEF-Cerus provides update on Intercept red blood cell system

May 9 (Reuters) - Cerus Corp

* Cerus announces exercise of additional BARDA contract options totaling $46.6 million to support intercept red blood cell system development

* Cerus corp- additional $46.6 million brings cerus' total allocation up to $88.4 million to date

* Cerus corp- recepi phase iii study protocol is under fda review, and redes phase iii study is open for enrollment

* Cerus corp- current allocations fund two of three expected phase iii studies for possible future pma submission Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below